| Dr Flora Rozhansky, MD | |
|
26 Jackson Ter, Newton, MA 02458-1430 | |
| (617) 965-0241 | |
| Not Available |
| Full Name | Dr Flora Rozhansky |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 37 Years |
| Location | 26 Jackson Ter, Newton, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063671931 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 219677 (Massachusetts) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Massachusetts General Physicians Organization Inc | 2466365820 | 3085 |
News Archive
Health care–associated infections (HAIs) account for a large proportion of the harms caused by health care and are associated with high costs. ... [Using a simulation, the researchers found that the] total annual costs for the 5 major infections were $9.8 billion (95% CI, $8.3-$11.5 billion), with surgical site infections contributing the most to overall costs (33.7% of the total), followed by ventilator-associated pneumonia (31.6%), central line–associated bloodstream infections (18.9%), C difficile infections (15.4%), and catheter-associated urinary tract infections (<1%). ... recent analyses indicate that at least 50% are preventable. ...
Eleven Biotherapeutics, a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, announced today it has completed a $35 million Series A financing co-led by Flagship Ventures and Third Rock Ventures. Proceeds from the financing will be used to build the research and development and business development teams for Eleven Biotherapeutics, in addition to advancing the company's portfolio of engineered proteins through clinical proof of concept.
The article published in volume 14 issue 6 of World Journal of Gastroenterology reports on one patient who presented to Dr Cosimo Sperti of University of Padua, Padova, Italy, in 2001 after an exploratory laparotomy performed in another hospital for an unresectable pancreatic cystic mass that had infiltrated the portal vein.
Hospira, Inc., a leading global specialty pharmaceutical and medication delivery company, today reported results for the first quarter ended March 31, 2010. Net sales for the quarter were $1.0 billion, and adjusted diluted earnings per share were $0.94.
› Verified 3 days ago
| Entity Name | Massachusetts General Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801874573 PECOS PAC ID: 2466365820 Enrollment ID: O20031111000434 |
News Archive
Health care–associated infections (HAIs) account for a large proportion of the harms caused by health care and are associated with high costs. ... [Using a simulation, the researchers found that the] total annual costs for the 5 major infections were $9.8 billion (95% CI, $8.3-$11.5 billion), with surgical site infections contributing the most to overall costs (33.7% of the total), followed by ventilator-associated pneumonia (31.6%), central line–associated bloodstream infections (18.9%), C difficile infections (15.4%), and catheter-associated urinary tract infections (<1%). ... recent analyses indicate that at least 50% are preventable. ...
Eleven Biotherapeutics, a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, announced today it has completed a $35 million Series A financing co-led by Flagship Ventures and Third Rock Ventures. Proceeds from the financing will be used to build the research and development and business development teams for Eleven Biotherapeutics, in addition to advancing the company's portfolio of engineered proteins through clinical proof of concept.
The article published in volume 14 issue 6 of World Journal of Gastroenterology reports on one patient who presented to Dr Cosimo Sperti of University of Padua, Padova, Italy, in 2001 after an exploratory laparotomy performed in another hospital for an unresectable pancreatic cystic mass that had infiltrated the portal vein.
Hospira, Inc., a leading global specialty pharmaceutical and medication delivery company, today reported results for the first quarter ended March 31, 2010. Net sales for the quarter were $1.0 billion, and adjusted diluted earnings per share were $0.94.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Flora Rozhansky, MD 26 Jackson Ter, Newton, MA 02458-1430 Ph: (617) 965-0241 | Dr Flora Rozhansky, MD 26 Jackson Ter, Newton, MA 02458-1430 Ph: (617) 965-0241 |
News Archive
Health care–associated infections (HAIs) account for a large proportion of the harms caused by health care and are associated with high costs. ... [Using a simulation, the researchers found that the] total annual costs for the 5 major infections were $9.8 billion (95% CI, $8.3-$11.5 billion), with surgical site infections contributing the most to overall costs (33.7% of the total), followed by ventilator-associated pneumonia (31.6%), central line–associated bloodstream infections (18.9%), C difficile infections (15.4%), and catheter-associated urinary tract infections (<1%). ... recent analyses indicate that at least 50% are preventable. ...
Eleven Biotherapeutics, a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, announced today it has completed a $35 million Series A financing co-led by Flagship Ventures and Third Rock Ventures. Proceeds from the financing will be used to build the research and development and business development teams for Eleven Biotherapeutics, in addition to advancing the company's portfolio of engineered proteins through clinical proof of concept.
The article published in volume 14 issue 6 of World Journal of Gastroenterology reports on one patient who presented to Dr Cosimo Sperti of University of Padua, Padova, Italy, in 2001 after an exploratory laparotomy performed in another hospital for an unresectable pancreatic cystic mass that had infiltrated the portal vein.
Hospira, Inc., a leading global specialty pharmaceutical and medication delivery company, today reported results for the first quarter ended March 31, 2010. Net sales for the quarter were $1.0 billion, and adjusted diluted earnings per share were $0.94.
› Verified 3 days ago
John D Freedman, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 29 Crafts St, Suite 470, Newton, MA 02458 Phone: 617-243-9509 | |
Ms. Marta Christov, MD, PHD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2000 Washington St Ste 460, Newton, MA 02462 Phone: 617-243-5420 | |
Caroline Stowell, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2014 Washington St, Medical Education, Newton, MA 02462 Phone: 617-243-6467 Fax: 617-243-6701 | |
John L Yang, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2014 Washington St, Newton, MA 02462 Phone: 617-219-1230 Fax: 617-831-7350 | |
Dr. Harley Anne Simeone, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 272 Centre St, Newton, MA 02458 Phone: 617-796-7170 Fax: 617-796-7171 | |
Meghan E Gange, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2014 Washington St, Newton, MA 02462 Phone: 617-243-6345 | |
Dr. Arthur Robert Kennedy Jr., M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2014 Washington St, Department Of Hospital Medicine, Newton, MA 02462 Phone: 617-243-6433 |